Microbot Medical Opens Federal Door for Its Vascular Robot
Microbot Medical ( NASDAQ: $MBOT) has signed a partnership with Lovell Government Services to expand access to its LIBERTY endovascular robotic system across major U.S. federal healthcare networks. Through Lovell, a Service‑Disabled Veteran‑Owned Small Business, LIBERTY will be positioned for purchase by more than 2,000 federal facilities, including the Veterans Health Administration, the Military Health System, and the Indian Health Service.
Under the deal, Lovell becomes Microbot’s SDVOSB vendor of record, listing LIBERTY on key federal procurement channels such as the VA Federal Supply Schedule (expected to go live in Q3 2026), GSA Advantage, DLA ECAT, and the DoD’s DAPA pricing program. This simplifies purchasing for VA, DoD, and IHS hospitals that want to adopt the technology.
Why it matters for patients
The agreement is aimed at improving access to advanced endovascular robotic procedures for:
- Veterans treated in VA medical centers.
- Active‑duty service members and their families in the Military Health System.
- Native American communities served by the Indian Health Service.
Microbot and Lovell highlight the potential for LIBERTY to support safer, more precise procedures and to extend high‑quality vascular care to more patients, particularly in systems that often face staffing and access challenges.
Investor angle
For investors, this is a commercial‑access catalyst rather than a clinical one: it doesn’t change the product, but it meaningfully broadens the addressable channel. Getting LIBERTY onto standard federal contracting vehicles lowers friction for VA and DoD buyers, potentially accelerating site adoption once the system is fully commercial. It also diversifies Microbot’s go‑to‑market beyond private hospitals, giving it exposure to large, relatively stable federal healthcare budgets focused on veterans and active‑duty populations.
